Trial · NCT07207278
Multi Omics Molecular Characteristics and Immunophenotyping of Lung Signet Ring Cell Carcinoma
NCT07207278, Recruiting, First People's Hospital of Hangzhou
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Multi Omics Molecular Characteristics and Immunophenotyping of Lung Signet Ring Cell Carcinoma. Trials, record NCT07207278. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07207278
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Multi Omics Molecular Characteristics and Immunophenotyping of Lung Signet Ring Cell Carcinoma
- NCT number
- NCT07207278
- Status
- Recruiting
- Enrollment
- 39 participants, estimated
- Lead sponsor
- First People's Hospital of Hangzhou
- Conditions
- Signet Ring Cell Carcinoma of the Lung
- Interventions
- Patients with specific TIME subtype and ALK fusion mutations (confirmed via RNA-seq and OncoKB annotation) will receive tyrosine kinase inhibitors (TKIs, e.g., alectinib or crizotinib) as first-line
- First posted
- 2025-10-03
- Last updated
- 2025-10-03
Source ClinicalTrials.gov
Registered outcomes7
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Week 8 Objective Response Rate (ORR) by RECIST v1.1 in ALK Fusion-Positive LSRCC Patients with Hybrid TIME Subtype | 8 weeks | Objective Response Rate (ORR), defined as the proportion of patients achieving Complete Response (CR) or Partial Response (PR) per RECIST v1.1 criteria, assessed via contrast-enhanced CT at Week 8 following initiation of TKI therapy. |
| Secondary | Progression-Free Survival (PFS) | From baseline until disease progression or death (assessed up to 24 months). | Time from initiation of TKI therapy to the first documented radiologic disease progression (as per RECIST v1.1) or death from any cause, whichever occurs first. |
| Secondary | Overall Survival (OS) | From baseline until death from any cause (assessed up to 36 months). | Time from initiation of TKI therapy to death from any cause. |
| Secondary | Duration of Response (DoR) | From first response until progression or death (assessed up to 24 months). | Among patients who achieve an objective response (CR or PR), the time from the first documented response to disease progression or death from any cause. |
| Secondary | Disease Control Rate (DCR) at Week 8 | 8 weeks | Proportion of patients achieving Complete Response (CR), Partial Response (PR), or Stable Disease (SD) per RECIST v1.1 at Week 8. |
| Secondary | Safety and Tolerability of TKI Therapy | From initiation of TKI therapy until 30 days after the last dose (assessed up to 24 months). | Incidence and severity of adverse events, laboratory abnormalities, and dose modifications, graded according to NCI-CTCAE version 5.0. |
| Secondary | Concordance Between Baseline mIHC-Defined TIME Subtypes and Treatment Outcomes | From baseline until disease progression or death (assessed up to 24 months). | Agreement between baseline multiplex immunohistochemistry (mIHC)-defined TIME subtypes (I, II, III) and real-world treatment outcomes (ORR and PFS) across the full cohort. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07207278
GET https://conductscience.org/api/trials/v1/NCT07207278/registered